A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation
about
Antidepressants for smoking cessationBreaking barriers in the genomics and pharmacogenetics of drug addictionWithin a smoking-cessation program, what impact does genetic information on lung cancer need to have to demonstrate cost-effectiveness?Model-based economic evaluations in smoking cessation and their transferability to new contexts: a systematic reviewPharmacogenetics of smoking cessation in general practice: results from the patch II and patch in practice trialsEconomic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature.Genetics and smoking cessation improving outcomes in smokers at riskGenetic variation in the dopamine pathway and smoking cessation.Nicotinic receptors and stages of nicotine dependence.A review of economic evaluations of genetic testing services and interventions (2004-2009).Pharmacogenetics of alcohol, nicotine and drug addiction treatments.Economic evaluation of smoking-cessation therapies: a critical and systematic review of simulation models.Multiparameter evidence synthesis in epidemiology and medical decision-making.Personalized medicine and tobacco-related health disparities: is there a role for genetics?Testing times.The DRD2/ANKK1 Taq1A polymorphism is associated with smoking cessation failure in patients with coronary heart disease
P2860
Q24201167-7516D941-CE9F-47E3-87A0-9A9ABC5FF07AQ30417717-D9747ACA-4F88-42D6-96E7-90F1A21DC6CFQ30496856-4A8E4183-F262-4D12-B359-75509A393558Q33697800-C8F9091E-D8FF-4539-AD4C-90328A2193A3Q35022995-07F2E23F-4A32-4B60-BFA6-4428C44DB77AQ35890606-A6A282C7-EBB6-4E28-B5A9-39DD1B8B5B52Q36319935-8ABC45D2-5E2F-4255-9E79-839BE6929758Q37264547-FA438DDA-057C-473C-9015-D7E283312C68Q37404292-1B13C60D-12F6-4566-8861-4C788D2FE6F3Q37832922-90BAEE74-5827-4D48-A23D-B9298ECC4305Q37848476-5907EB02-E7FF-492C-BA25-1BAFCEA56694Q38010473-83009AFD-AC42-45C1-BCA3-BE10354D0248Q40028428-989330C1-B857-4E01-A8C9-EA62E1DD7428Q42793934-99942A0A-B345-4DCC-83E6-FED0A9DA38FBQ52301801-88363327-C76C-416A-BB72-A8C56A92FFE3Q57605281-38D7CBB0-96A6-4911-A516-3596D10B01DF
P2860
A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
A cost-effectiveness analysis ...... t choice for smoking cessation
@ast
A cost-effectiveness analysis ...... t choice for smoking cessation
@en
type
label
A cost-effectiveness analysis ...... t choice for smoking cessation
@ast
A cost-effectiveness analysis ...... t choice for smoking cessation
@en
prefLabel
A cost-effectiveness analysis ...... t choice for smoking cessation
@ast
A cost-effectiveness analysis ...... t choice for smoking cessation
@en
P2860
P50
P1476
A cost-effectiveness analysis ...... t choice for smoking cessation
@en
P2093
Elaine C Johnstone
P2860
P304
P356
10.1080/14622200701767761
P577
2008-01-01T00:00:00Z